Gutopia vs Aidy: An Android IBD Tracker to Watch

Gutopia's listings describe local analysis; Aidy broadens UC tracking. Gutopia's Android and iPhone listings claim local analysis, delayed correlations, and infusion-cycle views. Aidy provides a broader UC workflow with SCCAI trends, detailed biologic scheduling, reports, and education.

Quick answer: For most people with UC, choose Aidy for free daily tracking, detailed biologic schedules, SCCAI trends, reports, and education. Gutopia is the genuine exception for someone prioritizing its claimed Android access and local-first analysis while accepting the app's limited public history.

Decision factor	Aidy	Gutopia (public claims)
Best for	Complete UC record	Claims local-first tracking
Daily IBD record	Symptoms, stool, food, treatment	Claims symptoms, meals, medicines, correlations
Treatment tools	Detailed biologic schedules	Claims infusion-cycle views
Reports and insights	SCCAI and reports	Claims local charts and exports
Access and cost	Free	Claims free Android and iPhone access
Overall pick	Aidy	Local-analysis exception

Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.

Gutopia is no longer Android-only

The current Google Play listing still calls its November 2025 build “Beta release 2 for open testing” and displays 0+ downloads. That makes “Gutopia Android beta” an accurate description of the Android channel. However, the iPhone listing shows a public version launched in October 2025, followed by two small updates that month. Apple currently displays two ratings, while the Android page shows no public review total.

This changes the answer for anyone seeking an Android UC tracker. Google Play lists Gutopia there, and Apple's listing gives iPhone users a version to assess. Both storefronts present the app without an upfront charge; Apple labels it Free and lists no in-app purchase. Its last visible updates were in 2025, so it remains less established than its feature list might suggest. A fair Gutopia IBD app review should separate promising design from evidence about long-term reliability, which the tiny public adoption signals cannot yet provide.

Gutopia has unusual local pattern tools

Gutopia’s materials say users can record pain, bowel movements, energy, mood, meals, medication, and infusion timing. Its official site claims lag-aware correlations across zero to seven days, infusion and flare-cycle tracking, and a three-to-seven-day flare-risk window. The iPhone description also claims local statistical methods and an AI-assisted meal feature. These are ambitious tools for a young Gutopia alternative, especially for people curious about delayed patterns.

The limits matter. Gutopia’s own listing says AI-generated content may contain errors and describes the product as a journal and visualization tool, not a medical device. A predicted window therefore should be treated as an app-generated signal, not proof that a flare is coming. Ulcerative colitis symptoms can include diarrhea, rectal bleeding, pain, urgency, and fatigue, and their severity varies (NIDDK). Symptoms alone cannot confirm active inflammation. Diagnosis and assessment may require blood or stool tests, endoscopy, and biopsies (NIDDK).

Aidy connects UC symptoms with treatment context

Aidy tracks symptom severity, Bristol stool entries, meals, medication adherence, doctor-ready reports, and automatically calculated SCCAI trends. The original SCCAI study developed the index from five clinical criteria and found strong correlation with more complex assessments (PubMed). It still represents self-reported clinical context, not a substitute for objective monitoring. AGA guidance favors combining symptoms with biomarkers in several UC situations (PubMed).

Treatment organization creates the clearest difference. Gutopia claims medication logging and infusion-cycle analysis. Its public pages do not document named biologic schedules, induction and maintenance phases, injection-site rotation, route or interval changes, or post-dose check-ins. Aidy includes all of those features across common biologics and biosimilars. It also joins adherence, food, stool, symptoms, SCCAI, and reports in one timeline. Food records can still be useful, though NIDDK recommends a healthy, balanced diet and notes that dietary needs vary (NIDDK). Neither app can determine whether a food caused inflammation.

Privacy is Gutopia’s strongest advantage

Gutopia says core analysis and health logs stay on the device. Its iPhone listing describes optional encrypted cloud backup, export, and deletion, while Apple’s privacy label says email, usage data, and diagnostics may be collected without being linked to identity. Google Play says no data is shared, although personal information, app activity, and performance data may be collected. These disclosures are not identical, so users should review the listing for their own platform. Aidy uses an account-connected service, and Apple says several data types may be linked to identity. Gutopia has the simpler local-first privacy story.

Gutopia’s current stores claim free downloads and show no listed paid upgrade. Aidy is free to use with no paid patient subscriptions. Aidy's free model includes the complete UC treatment and reporting workflow.

Among new IBD apps 2026 shoppers may encounter, Gutopia is worth watching for local analytics and Android access. Research on remote IBD care finds that web monitoring is broadly comparable with usual care for several outcomes and may slightly improve adherence, while evidence remains limited in important areas (Cochrane). Gutopia wins on local-first handling. Aidy wins overall for UC-specific scoring, biologic logistics, source-backed education, and a fuller care-team record.